Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Monopar Therapeutics Inc.NASDAQ: MNPR
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 152.6% from a year ago
Total equity stood at $135.39M at the end of Q1 FY2026, up 152.6% from a year earlier and down 1.8% from the prior quarter. Over 3 fiscal years it compounded at +139.0% a year.
Context
- Total equity amounted to 98.1% of total assets at the end of Q1 FY2026, up 0.8 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +152.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 137.83M USD
- Year-over-year change
- +150.4%
- 4-year CAGR
- +64.2%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 137.83M | +150.4% |
| FY2024 | 2024-12-31 | 55.04M | +885.0% |
| FY2023 | 2023-12-31 | 5.59M | -44.6% |
| FY2022 | 2022-12-31 | 10.09M | -46.7% |
| FY2021 | 2021-12-31 | 18.94M | — |
Total Equity vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +152.6% is the highest of 11, against a peer median of -4.9%.
- Total equity amounts to 98.1% of total assets for MNPR, versus a peer median of 74.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $554.32M USD | -25.1% | +31.1% | 85.0% | |
| Jun 2026 | $503.23M USD | -18.9% | -4.4% | 69.4% | |
| Sep 2026 | $454.3M USD | +72.1% | +236.5% | 89.9% | |
| Sep 2026 | $258.25M USD | -19.3% | -18.3% | 22.0% | |
| Mar 2026 | $186.47M USD | +69.1% | +2.7% | 90.9% | |
| Mar 2026 | $151.35M USD | +71.4% | -53.8% | 84.9% | |
| Mar 2026 | $135.39M USD | +152.6% | +139.0% | 98.1% | |
| Jun 2026 | $30.3M USD | +59.4% | -51.0% | 75.5% | |
| Mar 2026 | $21.2M USD | -73.2% | -26.8% | 9.7% | |
| Dec 2025 | -€21.69M EUR | -345.6% | — | 34.6% | |
| Mar 2026 | -$216.38M USD | +9.2% | — | 74.2% | |
| Peer median (excluding MNPR) | — | -4.9% | -11.4% | 74.8% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.